Biotech holding company Roivant Sciences raised $200M in funding at a whopping $7B valuation – TechCrunch

Roivant Sciences has had a bumpy couple of years, but that isn’t stopping investors from pouring more money into the four-year-old company, which aims to one day be a giant parent company for dozens of independent biopharmaceutical spinoffs — and is fulfilling that vision by creating one independent company at a time. Roivant’s newest financing…